<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03878082</url>
  </required_header>
  <id_info>
    <org_study_id>19MMHIS044e</org_study_id>
    <nct_id>NCT03878082</nct_id>
  </id_info>
  <brief_title>Propacetamol to Reduce Post Cesarean Section Uterine Contraction Pain</brief_title>
  <official_title>Perioperative Regular Usage of Propacetamol to Reduce Post Cesarean Section Uterine Contraction Pain and Opioid Consumption</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mackay Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mackay Memorial Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate that perioperative regular usage of propacetamol to reduce post cesarean section
      uterine contraction pain and opioid consumption
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The most common method of pain control after cesarean section is intravenous patient-control
      analgesia (IVPCA) with morphine. Multimodal analgesia could improve the quality of
      perioperative pain control and reduceside effects of opioids. Previous researches marked that
      perioperative pain after cesarean section includes somatic wound pain and visceral uterine
      contraction pain.

      According to Academy of Breastfeeding Medicine, propacetamol is a safe pain-killer for an
      expectant mother and almost free from breast milk after intravenous injection. This study is
      a prospective double-blind randomized-controlled trial to evaluate that propacetamol could
      reduce visceral uterine contraction pain after cesarean section. Post cesarean section women
      will divide into three groups:

        1. pain control with IVPCA for 2 days

        2. pain control with IVPCA and propacetamol 1g every 6 hours for 2 days

        3. pain control with IVPCA and propacetamol 2g every 6 hours for 2 days
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 12, 2019</start_date>
  <completion_date type="Anticipated">July 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of pain assessed by NRS</measure>
    <time_frame>Every 8 hours from post-anesthesia care unit to 2 days after the cesarean section</time_frame>
    <description>Change of pain assessed by Numerical Rating Scale: respondent selects a whole number (0-10 integers) that best reflects the intensity of the pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of treatment-relate adverse events</measure>
    <time_frame>Two days after the cesarean section</time_frame>
    <description>the complications or side effects during intervention, such as nausea/vomiting, skin itching, GI discomfort, urinary retention, and respiratory depression</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Opioid consumption</measure>
    <time_frame>Two days after the cesarean section</time_frame>
    <description>Comparison with the placebo group, the requirement of opoid</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Satisfaction assessed by the NRS</measure>
    <time_frame>Two days after the cesarean section</time_frame>
    <description>Participants' satisfaction about post-operative pain management assessed by Numerical Rating Scale: respondent selects a whole number (0-10 integers , dissatisfied -&gt; satisfied) that best reflects the satisfaction.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Uterine Pain</condition>
  <arm_group>
    <arm_group_label>propacetamol 1g</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>pain control with IVPCA and propacetamol 1g every 6 hours for 2 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>propacetamol 2g</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>pain control with IVPCA and propacetamol 2g every 6 hours for 2 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IVPCA</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>pain control with IVPCA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propacetamol 1g</intervention_name>
    <description>pain control with IVPCA and propacetamol 1g every 6 hours for 2 days</description>
    <arm_group_label>propacetamol 1g</arm_group_label>
    <other_name>Propacetamol 1g + IVPCA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propacetamol 2g</intervention_name>
    <description>pain control with IVPCA and propacetamol 2g every 6 hours for 2 days</description>
    <arm_group_label>propacetamol 2g</arm_group_label>
    <other_name>Propacetamol 2g + IVPCA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IVPCA</intervention_name>
    <description>pain control with IVPCA</description>
    <arm_group_label>IVPCA</arm_group_label>
    <arm_group_label>propacetamol 1g</arm_group_label>
    <arm_group_label>propacetamol 2g</arm_group_label>
    <other_name>IVPCA alone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnancy more than 36 weeks which is expected to receive Caesarean section

          -  Post Caesarean section woman, age greater than or equal to 20 years old

          -  ASA physical status class 1 or 2

        Exclusion Criteria:

          -  ASA physical status class 3 or above

          -  Less than 20 years old

          -  Past caesarean section for longitudinal wounds

          -  Undergone major abdominal surgery

          -  Chronic pain

          -  Allergic to morphine or Propacetamol

          -  Liver dysfunction

          -  Treatment with anticoagulant

          -  Emergency operation
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Post Caesarean section woman</gender_description>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chien-Chung Huang, MD</last_name>
    <role>Study Director</role>
    <affiliation>Mackay Memorial Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MacKay Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>104</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Valentine AR, Carvalho B, Lazo TA, Riley ET. Scheduled acetaminophen with as-needed opioids compared to as-needed acetaminophen plus opioids for post-cesarean pain management. Int J Obstet Anesth. 2015 Aug;24(3):210-6. doi: 10.1016/j.ijoa.2015.03.006. Epub 2015 Mar 23.</citation>
    <PMID>25936786</PMID>
  </reference>
  <reference>
    <citation>Ortiz MI, Ponce-Monter HA, Mora-Rodríguez JA, Barragán-Ramírez G, Barrón-Guerrero BS. Synergistic relaxing effect of the paracetamol and pyrilamine combination in isolated human myometrium. Eur J Obstet Gynecol Reprod Biol. 2011 Jul;157(1):22-6. doi: 10.1016/j.ejogrb.2011.02.011. Epub 2011 Mar 24.</citation>
    <PMID>21439705</PMID>
  </reference>
  <reference>
    <citation>Gadsden J, Hart S, Santos AC. Post-cesarean delivery analgesia. Anesth Analg. 2005 Nov;101(5 Suppl):S62-9. Review.</citation>
    <PMID>16334493</PMID>
  </reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>March 7, 2019</study_first_submitted>
  <study_first_submitted_qc>March 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2019</study_first_posted>
  <last_update_submitted>August 12, 2019</last_update_submitted>
  <last_update_submitted_qc>August 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mackay Memorial Hospital</investigator_affiliation>
    <investigator_full_name>Chien-Chung,Huang</investigator_full_name>
    <investigator_title>attending physician, department of anesthesiology</investigator_title>
  </responsible_party>
  <keyword>cesarean section</keyword>
  <keyword>uterine contraction pain</keyword>
  <keyword>propacetamol</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Propacetamol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

